about our portfolio

Portage has built a portfolio of five technology platforms initially yielding ten candidates that uniquely target different cancer resistance pathways.

We’re leading scientists and clinicians through the development of immunotherapies that augment responses in immunogenic tumors and help initiate a response in non-immunogenic tumors. The flagship platform within our portfolio is our invariant natural killer T-cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. Our portfolio also includes antibodies, small molecules and protein therapeutics delivered by novel intratumoral formulations (PORT-1), nanolipogels (PORT-4), and virus-like particles (PORT-5).

Pipeline

PLATFORM
TECHNOLOGY
ASSET
INDICATION
STAGE
TECHNOLOGY
iNKT Agonists
Liposomal Formulations
ASSET
IMM60
INDICATION
Melanoma
STAGE
Phase I/II
TECHNOLOGY
iNKT Agonists
Liposomal Formulations
ASSET
IMM60 + Keytruda
INDICATION
Melanoma
STAGE
Phase I/II
TECHNOLOGY
iNKT Agonists
Liposomal Formulations
ASSET
IMM60 + Keytruda
INDICATION
NSCLC
STAGE
Phase I/II
TECHNOLOGY
iNKT Agonists
Liposomal Formulations
ASSET
IMM60 + Cell Therapy
INDICATION
Solid Tumors
STAGE
Preclinical
TECHNOLOGY
iNKT Agonists
Nanoparticle co-formulations
ASSET
(IMM60 / NY-ESO-1) + Keytruda
INDICATION
NY-ESO-1 Positive Tumors
STAGE
Phase I/II
TECHNOLOGY
iNKT Agonists
Nanoparticle co-formulations
ASSET
(IMM60 / NY-ESO-1) + Keytruda
INDICATION
NY-ESO-1 Bladder & Ovarian
STAGE
Phase I/II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6
INDICATION
Early Stage Breast
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6 + Keytruda
INDICATION
Pancreatic
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6 + Keytruda
INDICATION
Non MSI CRC
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6 + Keytruda
INDICATION
Cholangiocarcinoma
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6 + Keytruda
INDICATION
Squamous Cell
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6 + Yervoy
INDICATION
Breast
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6 + Yervoy
INDICATION
HCC
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6 + Yervoy
INDICATION
Sarcoma
STAGE
Phase II
TECHNOLOGY
Intratumoral Amphiphilic Solutions
ASSET
INT230-6
INDICATION
Solid Tumor
STAGE
Phase II
TECHNOLOGY
Nanolipogel Co-Formulations (NGLs)
ASSET
SAUG 1 (PD1 + VEGF TKI)
INDICATION
Solid Tumor
STAGE
Preclinical
TECHNOLOGY
Nanolipogel Co-Formulations (NGLs)
ASSET
SAUG2 (PD1 + CTLA4)
INDICATION
Solid Tumor
STAGE
Preclinical
TECHNOLOGY
VLP-STING
ASSET
STIM1 + approved agent
INDICATION
Solid Tumor
STAGE
Preclinical

There is a significant unmet need to better serve patients who do not respond to existing checkpoint inhibitors. We seek novel treatments to improve responses to these therapies.